Medtronic Invests in Chinese Medtech Firm CardiACC to Strengthen Electrophysiology Portfolio

01

Revenue364100 million USD

Recorded the highest growth in a decade

Local Time6Month3On [date], Medtronic announced the results for the period ending4Month24Daily2026Fiscal year and fourth-quarter financial results, setting a record for the past10the strongest revenue growth over the years. 

2026Fiscal YearMedtronicRevenueAchieve364hundred million USD, representing an increase calculated based on the reported data8.4%, with an organic growth rate of5.8%. Based on Generally Accepted Accounting Principles (GAAP) net profit and diluted earnings per share were respectively48.01billion USD and3.73US dollars, increased by3.0%and3.3%。

Among them,Q4Revenue98.07hundred million USD, year-on-year growth9.9%；Net Profit12.59hundred million US dollars,Year-on-Year Growth18.7%。

MedtronicEstimated2027The fiscal year's organic revenue growth rate will be at6.75%To7.25%Between。

By business line,2025YearCardiovascularThe Department Remains the "Top Sales Performer"，Last Year's Revenue139.76hundred million USD, an increase of12%Among themCardiac Rhythm and Heart Failure BusinessGrowth17.4%, showing the most outstanding performance;Structural Heart and Vascular Businesshas also achieved7.4%growth.

NeuroscienceNeuromodulation and Surgical Care DepartmentDepartment'sEmergency Care and Vital Signs MonitoringBusiness, with growth rate also exceeding7%。

Focus on2026Q4From this perspective, the electrophysiology sector has achieved outstanding results,Global Revenue Growth of Cardiac Ablation Solutions78%, U.S. Market Growth124%, further increasing market share in the United States8percentage points。

Notably, Medtronic is seeking additional new leverage to drive robust growth in the electrophysiology sector.

02

Continuous high-frequency investment and acquisition

Chinese Innovative Enterprises Regain Favor

In technology-intensive sectors, the key to market success lies in incremental innovation.

On the same day as the financial report release, MedtronicAnnounced Two More Strategic Investment Deals, Doubling DownIntracardiac Echocardiography (ICE) Catheter Technology。

Both target companies involved in this transaction possessICETechnical Capabilities:Located in California,Beluga Medical，ShangIn the preclinical stage, developing a new generationICEProduct;Headquartered in Shenzhen, ChinaCardiACC，The product has been2025Year Received NationalApproved by the Drug Administration, currentlyIn the early commercialization stage。

ICEIt is an important component of ablation therapy.，Can be used in cardiac electrophysiologyDuring the examination, it provides real-time, high-resolution cardiac imaging for arrhythmias such as atrial fibrillation. Medtronic plans toICEIntegrated intoAffera™Localization and Ablation System.These investments also contribute toConsolidationIts strong presence in the field of electrophysiologyDevelopment Momentum。

Investment in the cardiac ablation field has continued the pace of Medtronic’s recent strategic transactions.Currently,MedtronicIn progressContinuously prioritize high-growth opportunities to complement its core business。

Since the beginning of this year, Medtronic has disclosedMultiple mergers and acquisitions and venture capital investments to strengthen the portfolio, accelerate growth, and expand into high-growth related sectors。

5Month,Medtronic AnnouncesProposedOne-time payment of approximately6.5hundred million USD，AcquisitionFocused onChronic Pain ManagementofSPR Therapeutics, Inc.，withIncreasePNSTherapy。

4Month,Medtronic Announces CompletionleYesCathWorksof5.85Acquisition for Hundreds of Millions of US Dollars, thisA company dedicated to revolutionizing the diagnosis and treatment of coronary artery disease,PossessThe only one based on angiography technologyFFRvalue system.

Possessing Key Innovative Technologies in the Neurovascular FieldScientia Vascular，has also become a target of Medtronic. The catheter products developed by the company can provide simple and efficient treatment solutions for complex neurovascular diseases, improving the efficiency of interventional surgery.

In the first half of this year, Medtronic also invested in another Chinese company——Pam Medical. This companyIndependently DevelopedPulmonary Artery Denervation (PADN) The system is the world’s first minimally invasive interventional therapy product, currentlyCompleted oversubscription1hundred million USD in financing, led by Medtronic.

Behind the frequent attention on Chinese medical device companies lies the enhanced innovation capability of domestic firms in recent years, with an increasing number of local enterprises eager to venture into the forefront of global medical device innovation. As of June 3, the National Medical Products Administration had approved 427 innovative medical devices for market launch. In overseas markets, Chinese medical devices have also gained greater clinical recognition than ever before.

In the future, stories of foreign and local companies joining forces for innovation may continue to unfold.

END